natgillin/translations-raw huggingface dataset:
Retention in treatment was high, with 96.4% of Sixmo patients and 94.4% of sublingual buprenorphine patients completing the study. 
Stopnja vztrajanja bolnikov v programu zdravljenja je bila visoka - 96,4 % bolnikov v skupini z zdravilom Sixmo in 94,4 % bolnikov v skupini s podjezičnim buprenorfinom.
Please note: Buprenorphine can cause severe, possibly fatal, breathing depression (shortness of breath or stops breathing) in children who are accidentally exposed to it. 
Pozor: buprenorfin lahko povzroči hudo, lahko celo usodno, depresijo dihanja (kratko sapo ali prenehanje dihanja) pri otrocih, ki so buprenorfinu nehote izpostavljeni.
Blood and lymphatic system disorders uncommon lymphadenopathy, neutropenia 
Bolezni krvi in limfatičnega sistema občasni limfadenopatija, nevtropenija
The implants should be positioned in a fan-shaped distribution at least 5 mm from the incision, and palpable after placement. 
Implantati morajo biti pahljačasto razporejeni vsaj 5 mm stran od reza in morajo biti po namestitvi otipljivi.
In each of the two studies, the proportion of subjects requiring supplemental SL BPN was significantly higher in the placebo group than in the Sixmo group (90.9% and 66.7% of subjects, with mean days of use per week of 2.17 and 1.27, in PRO-805 and PRO-806, respectively). 
V vsaki od obeh študij je bil delež preiskovancev, ki so potrebovali dodatni SL BPN, pomembno višji v skupini, ki je dobivala placebo, kot v skupini, ki je dobila zdravilo Sixmo (90,9 % proti 66,7 % preiskovancev, s povprečnim številom dni uporabe na teden 2,17 v študiji PRO-805 oziroma 1,27 v študiji PRO-806).
Do not breast-feed during Sixmo treatment, as buprenorphine passes into breast milk. 
• Dojenje Med uporabo zdravila Sixmo ne dojite, ker buprenorfin prehajata v materino mleko.
• instrument stand covered with sterile drape 
• instrumentarska mizica, prekrita s sterilno prevleko,
The implants will then be inserted under the skin in the inner side of the upper arm. 
Implantate bo nato vstavil pod kožo na notranjo stran nadlakti.
Insertion and removal of the Sixmo implants must be performed by a physician who is competent in minor surgery and has been trained to conduct the insertion and removal procedure. 
Implantate Sixmo sme vstavljati in odstranjevati le zdravnik, ki je pristojen za izvajanje manjših kirurških posegov in je usposobljen za izvajanje postopkov vstavljanja in odstranjevanja.
Buprenorphine is an opioid partial agonist/antagonist which binds to the μ (mu) and κ (kappa) 
Buprenorfin je delni agonist/antagonist opioidov, ki se veže na receptorje μ (mu) in κ (kapa) v možganih.
If implant(s) or implant fragment(s) are not removed during a removal attempt, the patient should undergo imaging for localisation as soon as is feasible with the subsequent removal attempt performed on the same day as localisation. 
Če med postopkom odstranjevanja implantata/implantatov ali delcev implantata ne morete odstraniti, je bolnika treba slikati za določitev položaja čim prej, ko je mogoče, in še isti dan znova poskusiti s postopkom odstranjevanja.
For patients returning for subsequent treatment with Sixmo, preparations should be made to perform both the removal and insertion of Sixmo at the same visit. 
Pri bolnikih, ki pridejo zaradi nadaljevanja zdravljenja z zdravilom Sixmo, se je treba pripraviti tako na odstranitev kot tudi vstavitev novih implantatov Sixmo v sklopu enega obiska.
However, pups exposed to opioids postnatally exhibited significant body weights reductions. 
Se je pa pri mladičih, ki so bili opioidom izpostavljeni v ponatalnem obdobju, telesna masa pomembno zmanjšala.
Therefore, a higher potential for toxicity exists with opioid administration. 
Zato obstaja večja verjetnost za toksičnost pri dajanju opioidov.
If the implant is encapsulated, or you see dimpling, use the scalpel to shave the adhering tissue to release the implant. 
Če je implantat vraščen ali pogreznjen, s skalpelom odstranite prilepljeno tkivo, da sprostite implantat.
Patients with a history of keloid or hypertrophic scar formation should not undergo subcutaneous insertion, as difficulties in retrieving the implant are possible. 
Pri bolnikih, ki imajo v anamnezi keloidno ali hipertrofično brazgotinjenje, subkutana vstavitev ni dovoljena, saj bi se pri odstranjevanju implantatov lahko pojavile težave.
• are using naltrexone or nalmefene to treat alcohol or opioid dependence 
• če uporabljate naltrekson ali nalmefen za zdravljenje odvisnosti od alkohola ali opioidov;
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost za učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1 Huda respiratorna insuficienca
Please note: Buprenorphine can cause severe, possibly fatal, respiratory depression in children who are accidentally exposed to it. 
Pomnite: Buprenorfin lahko povzroči hudo, lahko celo usodno, depresijo dihanja pri otrocih, ki so mu nehote izpostavljeni.
• painful period, erectile dysfunction 
• boleča menstruacija, motnje erekcije,
Patients with mild to moderate hepatic impairment (Child-Pugh A and B) should be monitored for signs and symptoms of toxicity or overdose caused by increased levels of buprenorphine (miosis, lip cyanosis, sedation, bradycardia, hypotension, respiratory depression). 
Bolnike z blago do zmerno okvaro jeter (Child-Pugh A in B) je treba spremljati glede znakov in simptomov toksičnosti ali prevelikega odmerjanja, ki ga povzročajo povišane ravni buprenorfina (mioza, cianoza ustnic, sedacija, bradikardija, hipotenzija, depresija dihanja).
These are very common or common adverse reactions with buprenorphine. 
To so zelo pogosti ali pogosti neželeni učinki pri jemanju buprenorfina.
• medicines to treat HIV infections with active substance names ending in “navir”, such as ritonavir, nelfinavir, amprenavir, fosamprenavir 
• zdravila za zdravljenje okužbe s HIV, ki vsebujejo učinkovino, katere ime se konča na „navir“, kot so ritonavir, nelfinavir, amprenavir, fosamprenavir;
You may remove the pressure bandage after 24 hours and the adhesive bandage after five days. 
Kompresijski povoj lahko odstranite po 24 urah, obliž pa po petih dneh.
The MAH shall also ensure that in each MS where SIXMO is marketed, each patient being prescribed this SC implant receives from the treating physician the Patient Information Leaflet (PIL) and a (wallet-sized) patient alert card, to be carried out at all times while on SIXMO treatment, and presented to other health care professionals (HCP) before any medical treatment / intervention is carried out. 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bo v vseh državah članicah, kjer se zadravilo Sixmo trži, vsak bolnik, ki prejme ta podkožni implantat, od lečečega zdravnika prejel navodilo za uporabo za bolnika in opozorilno kartica za bolnika (v velikosti, primerni za v denarnico), ki jo mora imeti pri sebi ves čas med zdravljenjem z zdravilom Sixmo in jo pokazati drugim zdravstvenim delavcem pred vsakim zdravljenjem/posegom.
Patients treated with CYP inhibitors (e.g. ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone, verapamil, diltiazem, amiodarone, amprenavir, fosamprenavir, aprepitant, fluconazole, erythromycin and grapefruit juice) should be monitored for signs and symptoms of toxicity or overdose (miosis, lip cyanosis, sedation, bradycardia, hypotension, respiratory depression). 
Bolnike, ki se zdravijo z zaviralci encima CYP (npr. ritonavir, ketokonazol, itrakonazol, troleandomicin, klaritromicin, nelfinavir, nefazodon, verapamil, diltiazem, amiodaron, amprenavir, fosamprenavir, aprepitant, flukonazol, eritromicin in sok grenivke) je treba spremljati glede zankov in simptomov toksičnosti ali prevelikega odmerjanja (mioza, cianoza ustnic, sedacija, bradikardija, hipotenzija, depresija dihanja).
• abnormal mean cell volume 
• nenormalen povprečni celični volumen,
Step 5: Lower the applicator to a horizontal position; lift the skin up with the tip of the applicator, but keep the cannula in the subcutaneous connective tissue (Figure 6). 
5. korak: Aplikator spustite v vodoravni položaj, s konico aplikatorja dvignite kožo tako, da bo kanila še naprej v subkutanem vezivnem tkivu (slika 6).
The spectrum of abnormalities ranges from transient asymptomatic elevations in hepatic transaminases to case reports of hepatic failure, hepatic necrosis, hepatorenal syndrome, hepatic encephalopathy and death. 
Spekter nenormalnih izvidov se giblje od prehodnega asimptomatskega zvišanja jetrnih transaminaz do odpovedi jeter, jetrne nekroze, hepatorenalnega sindroma, hepatične encefalopatije in smrti.
CYP3A4 inhibitors may inhibit the metabolism of buprenorphine resulting in increased Cmax and AUC of buprenorphine and norbuprenorphine. 
Zaviralci CYP3A4 lahko zavrejo presnovo buprenorfina, kar povzroči povečanje vrednosti Cmax in AUC buprenorfina in norbuprenorfina.
Patients who elect to discontinue Sixmo treatment should be monitored for withdrawal syndrome, with consideration given to use of a tapering dose of sublingual buprenorphine. 
Bolnike, ki se odločijo za prekinitev zdravljenja z zdravilom Sixmo, je treba spremljati glede odtegnitvenega sindroma in pri tem razmisliti o zmanjšanem odmerku podjezičnega buprenorfina.
Prior to the launch of SIXMO in each Member State (MS), the Marketing Authorisation Holder (MAH) must agree the content and format of the educational materials, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority (NCA). 
• Dodatni ukrepi za zmanjševanje tveganj Pred prihodom zdravila SIXMO na trg v posamezni državi članici se mora imetnik dovoljenja za promet z zdravilom s pristojnim nacionalnim organom dogovoriti glede vsebine in oblike izobraževalnega gradiva, vključno sredstvi obveščanja, načini razdeljevanja in drugimi vidiki programa.
Step 15: Pick up the skin edge with Adson single toothed tissue forceps and separate the tissues above and below the visible implant, using an iris scissors or a curved mosquito forceps (Figure 16). 
15. korak: S kirurško pinceto Adson privzdignite rob kože in ločite tkivo nad vidnim implantatom in tkivo pod njim, pri tem pa uporabite kratke škarje ali ukrivljene hemostatske prijemalke (slika 16).
hypercapnia, pre-existing respiratory depression or kyphoscoliosis [curvature of spine leading to potential shortness of breath]). 
hiperkapnijo, obstoječo respiratorno depresijo ali kifoskoliozo [ukrivljenost hrbtenice, ki povzroča kratko sapo]) uporabljati previdno.
This study enrolled 84 patients in the Sixmo group and 89 patients in the sublingual buprenorphine group, with a median age (range) of 36 (21 to 63) years and 37 (22 to 64) years in the Sixmo and sublingual buprenorphine groups, respectively. 
Ta študija je vključevala 84 bolnikov v skupini, ki je dobila zdravilo Sixmo, in 89 bolnikov, ki so prejeli podjezični buprenorfin, mediana starosti (razpon) je v skupini z zdravilom Sixmo znašala 36 (21 do
Sixmo implants are intended to be in place for 6 months of treatment and provide a sustained delivery of buprenorphine. 
Implantati Sixmo so predvideni za vstavitev za 6 mesecev zdravljenja in stalno dovajajo buprenorfin.
Appropriate precautions, such as the conduct of patient follow-up visits according to the patient's needs and the treating physician's clinical judgement, should be taken during Sixmo treatment. 
Med zdravljenjem z zdravilom Sixmo je treba izvesti ustrezne previdnostne ukrepe, kot je izvajanje spremljevalnih obiskov bolnika v skladu z bolnikovimi potrebami in klinično presojo lečečega zdravnika.
• increased or decreased weight, including abnormal weight gain 
• povečanje ali zmanjšanje telesne mase, vključno z nenormalnim povečanjem telesne mase,
A key secondary endpoint in Study PRO-806 was the difference in proportions of urine samples that were negative for opioids over 24 weeks for Sixmo versus sublingual buprenorphine. 
Ključni sekundarni opazovani dogodek v študiji PRO-806 je bila razlika v deležih vzorcev urina, ki so bili v 24 tednih negativni za opioide v skupini z zdravilom Sixmo v primerjavi s skupino, ki je jemala podjezični buprenorfin.
Step 7: While holding the cannula in place, unlock the obturator and remove the obturator. 
7. korak: Medtem ko kanilo držite pri miru, odklenite mandren in ga odstranite.
• consistency in compliance with clinic visit requirements 
• stalno izpolnjevanje zahtev v okviru kontrolnih pregledov,
Buprenorphine has the potential to be abused and is prone to criminal diversion. 
Zloraba in preusmerjanje uporabe Buprenorfin ima potencial, da se ga zlorablja in preusmerja v kaznivo uporabo.
• sleeplessness, anxiety, hostility, nervousness 
• nespečnost, tesnoba, sovražnost, živčnost,
Also, scan or input the details of the implant procedure into the patient's medical records. 
Prav tako v bolnikovo zdravstveno kartoteko zabeležite oz. vnesite podatke o postopku implantacije.
Only a healthcare professional who is competent in minor surgery and is trained in the insertion of Sixmo should perform the procedure, using only the implant applicator, with the recommended local anaesthetic available. 
Postopek lahko izvede samo zdravstveni strokovnjak, ki je pristojen za izvajanje manjših kirurških posegov in je usposobljen za vstavljanje zdravila Sixmo, pri tem postopku pa mora uporabljati aplikator za implantate in imeti na voljo priporočeni lokalni anestetik.
• latest date on which the implant must be removed Keep this card in a safe place, since the information on the card may make it easier to carry out removal. 
To kartico shranite na varnem mestu, ker informacije na kartici lahko olajšajo odstranjevanje implantatov.
General precautions relevant to the administration of opioids 
Splošna opozorila, ki se nanašajo na dajanje opioidov
• Infection may occur at the site of the insertion or removal of the implant. 
• Na mestu vstavitve ali odstranjevanja implantata se lahko pojavi okužba.
• That the card-holder is using SIXMO (buprenorphine only opioid-dependence treatment via SC implant located at the inner side of the upper arm) 
• imetnik te kartice uporablja zdravilo Sixmo (zdravilo za zdravljenje odvisnosti od opioidov, ki vsebuje samo buprenorfin, v obliki podkožnega implantata na notranji strani nadlakti);
Therefore, breastfeeding should be discontinued during treatment with Sixmo. 
Med zdravljenjem z zdravilom Sixmo je treba prenehati z dojenjem.
Place a small adhesive bandage over the insertion site. 
Čez mesto vstavitve namestite manjši obliž.
Healthcare professionals should consider the potential role and contribution of buprenorphine when given in conjunction with other CNS depressant medicinal products, CYP3A4 inhibitors, other opioids and in cases of hepatic impairment when determining whether the implants should be removed (see sections 4.4 and 4.5). 
Zdravstveni strokovnjaki morajo pri odločanju glede odstranitve implantatov upoštevati potencialno vlogo in prispevek buprenorfina, kadar se uporablja v kombinaciji z drugimi depresorji centralnega živčnega sistema, zaviralci encima CYP3A4, drugimi opioidi in v primerih okvare jeter (glejte poglavji 4.4 in 4.5).
How to use Sixmo 
Kako uporabljati zdravilo Sixmo
Sixmo is formulated as a diversion and abuse deterrent formulation. 
Zdravilo Sixmo je formulirano tako, da odvrača od preusmerjanja in zlorabe.
• reduced sense of touch or sensation 
• zmanjšan občutek dotika ali zmanjšane čutne zaznave,
• sutures, such as 4-0 Prolene™ with an FS-2 cutting needle (may be absorbable) 
• kirurške niti, na primer 4-0 Prolene™ z rezalno iglo FS-2 (lahko je resorbilna).
The following factors should be considered when determining clinical stability and suitability for Sixmo treatment: 
Pri določanju klinične stabilnosti in primernosti zdravljenja z zdravilom Sixmo je treba upoštevati naslednje dejavnike:
Instruction for location of implants prior to removal Verify the location of the implants by palpation. 
Navodila glede iskanja mesta implantatov pred odstranitvijo S tipanjem preverite lokacijo implantatov.
Name and address of the manufacturer(s) responsible for batch release 
ČEŠKA REPUBLIKA Ime in naslov izdelovalca (izdelovalcev), odgovornega (odgovornih) za sproščanje serij
• medicines to treat fungal infections, like thrush, with active substance names ending in “azole”, such as ketoconazole, itraconazole, fluconazole 
• zdravila za zdravljenje glivičnih okužb, npr. kandidoze, ki vsebujejo učinkovino, katere ime se konča na „azol“, kot so ketokonazol, itrakonazol, flukonazol;
Sixmo implants are intended to be in place for 6 months and provide a continuous delivery of buprenorphine. 
Implantati Sixmo so predvideni za vstavitev za 6 mesecev in stalno dovajajo buprenorfin.
Step 1: The patient should lie on their back, with the intended arm flexed at the elbow and externally rotated, so that the hand is positioned next to the head. 
1. korak: Bolnik naj leži na hrbtu, roka naj bo v komolcu upognjena in obrnjena navzven, tako da je dlan poleg glave.
Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment. 
4.1 Terapevtske indikacije Zdravilo Sixmo je indicirano za nadomestno zdravljenje odvisnosti od opioidov v okviru medicinskega, socialnega in psihološkega zdravljenja pri klinično stabilnih odraslih bolnikih, ki ne potrebujejo več kot 8 mg/dan podjezičnega buprenorfina.
Patients who develop hepatic impairment while being treated with Sixmo should be monitored for signs and symptoms of toxicity or overdose. 
Če se pri bolnikih okvara jeter pojavi med zdravljenjem z zdravilo Sixmo, je treba te bolnike spremljati glede znakov in simptomov toksičnosti ali prevelikega odmerjanja.
Sixmo is a white/off-white to pale yellow rod-shaped implant, 26.5 mm long and 2.4 mm in diameter. 
Zdravilo Sixmo je bel/belkast do bledo rumen implantat v obliki paličice, z dolžino 26,5 mm in premerom 2,4 mm.
• If the expelled implant is not intact, the healthcare professional should palpate the insertion location to identify the location of any remaining partial implant. 
• Če iztisnjeni implantat ni cel, mora zdravstveni strokovnjak s tipanjem pregledati mesto vstavitve, da poišče lokacijo drugega dela implantata.
Adverse drug reactions were categorized as implant or non-implant adverse reactions. 
Neželeni učinki zdravila so bili razvrščeni kot neželeni učinki, povezani z implantatom ali nepovezani z implantatom.
Opioids should be used with caution in patients with myxoedema, hypothyroidism or adrenal cortical insufficiency (e.g. Addison's disease). 
Pri uporabi opioidov pri bolnikih z miksedemom, hipotiroidizmom ali adrenokortikalno insuficienco (na primer Addisonova bolezen) je potrebna previdnost.
The treating physician should consider implant removal if: 
Kriteriji za prekinitev zdravljenja Lečeči zdravnik mora o odstranitvi implantata razmisliti v naslednjih primerih:
If spontaneous expulsion of the implant occurs after insertion, the following steps should be taken: 
Če po vstavitvi pride do spontanega iztisa implantata, je treba storiti naslednje:
Counsel the patient on proper aseptic wound care. 
Bolniku svetujte, kako naj ustrezno aseptično neguje rano.
Naloxone may be of value for the management of buprenorphine overdose. 
Nalokson lahko pomaga pri obvladovanju prevelikega odmerjanja buprenorfina.
Pups born tended to weigh less on postnatal day 1 compared with controls. 
Skoteni mladiči so 1. ponatalni dan v primerjavi s kontrolami v večini primerov tehtali manj.
Apply the sterile drape to the patient's arm. Anaesthetise the incision site and the subcutaneous space containing the implants (for example, by injecting 5 to 7 mL lidocaine 1% with adrenaline 1:100,000). 
Mesto reza in subkutani prostor, kjer so implantati, anestezirajte (na primer z injiciranjem 5 do 7 ml 1 % lidokaina z adrenalinom 1 : 100.000).
Retract the applicator, bevel-up, until the distal marking of the cannula is visible at the incision opening (the sharp tip remaining in the subcutaneous space). 
Aplikator s poševnino konice navzgor vlecite nazaj, dokler distalna oznaka kanile ni vidna na odprtini reza (ostra konica ostaja subkutano).
Sixmo implants must be inserted, removed, and patients monitored by a healthcare professional familiar with the procedure, with experience in the management of opioid addiction. 
Vstavljanje in odstranjevanje implantatov Sixmo ter spremljanje bolnika mora izvajati zdravstveni strokovnjak, ki je seznanjen s postopkom in ima izkušnje z obvladovanjem odvisnosti od opioidov.
Instruct the patient that the pressure bandage can be removed after 24 hours and the adhesive bandage removed in three to five days, and to apply an ice pack on the arm for 40 minutes every two hours for the first 24 hours, then as needed. 
Bolniku povejte, da lahko kompresijski povoj sname po 24 urah, obliž pa po treh do petih dneh, ter da naj v prvih 24 urah na roki drži ledeni obkladek 40 minut vsaki dve uri, kasneje pa po potrebi.
No recommendation on posology can be made. 
Poročil o odmerjanju ni mogoče dati.
• Benzodiazepines: This combination may result in death due to respiratory depression of central origin. 
Buprenorfin je treba uporabljati previdno pri sočasnem dajanju z: • benzodiazepini: ta kombinacija lahko povzroči smrt zaradi depresije dihanja centralnega izvora.
• liquid adhesive 
• tekoči adheziv,
Sixmo should also be administered with caution in patients with a history of connective tissue disease (e.g. scleroderma) or history of recurrent methicillin-resistant Staphylococcus aureus infections. 
Pri dajanju zdravila Sixmo je potrebna previdnost tudi pri bolnikih, ki imajo v svoji anamnezi bolezen vezivnega tkiva (npr. skleroderma) ali ponavljajoče okužbe z bakterijo Staphylococcus aureus, odporno proti metilicinu.
The Sixmo PK was assessed in opioid-dependent patients treated with Sixmo in studies TTP-400-0201, PRO-810, PRO-805, PRO-806, PRO-807 and PRO-811. 
Farmakokinetične lastnosti zdravila Sixmo so ocenjevali pri bolnikih, odvisnih od opioidov, ki so se zdravili z zdravilom Sixmo v študijah TTP-400-02-01, PRO-810, PRO-805, PRO-806, PRO-807 in PRO-811.
• 4 Sixmo implants 
• 4 implantati Sixmo,
Sixmo is not recommended during pregnancy, nor in women of childbearing age not using contraception. 
Uporaba zdravila Sixmo ni priporočljiva med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
Sixmo is contraindicated in patients with a history of keloid or hypertrophic scar formation at the site where Sixmo would be implanted, as difficulties in retrieving the implant are possible (see section 
Zdravilo Sixmo je kontraindicirano pri bolnikih, ki imajo v svoji anamnezi keloidno ali hipertrofično brazgotinjenje na mestu, kjer bi bilo treba vstaviti implantate Sixmo, saj bi se pri odstranjevanju implantatov lahko pojavile težave (glejte poglavje 4.3).
LIST OF EXCIPIENTS Excipient: Ethylene vinyl acetate copolymer 
SEZNAM POMOŽNIH SNOVI Pomožna snov: kopolimer etilen vinil acetata
PATIENT ALERT CARD 
OPOZORILNA KARTICA ZA BOLNIKA
Figure 3: Plasma buprenorphine concentrations after insertion of Sixmo (concentrations up to day 28 are based on study PRO-810, while concentrations after day 28 are based on studies PRO-805, PRO-806, PRO-807 and PRO-811) 
Slika 3: Koncentracije buprenorfina v plazmi po vstavitvi zdravila Sixmo (koncentracije do 28. dneva temeljijo na študiji PRO-810, koncentracije po 28. dnevu pa na študijah PRO-805, PRO-806, PRO-807 in PRO-811)
The mortality index was significantly increased in the buprenorphine groups. 
Stopnja umrljivosti je bila v skupini z buprenorfinom pomembno zvišana.
If another set of implants is not inserted on the same day as the previous set is removed: A dose of between 2 and 8 mg buprenorphine daily, given under the tongue, is recommended until repeat treatment occurs. 
Če vam ne vstavijo novega kompleta implantatov isti dan, ko so vam odstranili stare: Priporočljiva je uporaba odmerka od 2 do 8 mg na dan, ki se daje pod jezik, dokler vam ne uvedejo ponovnega zdravljenja.
Ask your doctor or pharmacist for advice in these cases. 
V teh primerih se posvetujte z zdravnikom ali farmacevtom.